Cambridge Healthtech Institute’s Second Annual

Protein Aggregates and Particles

Tools and Techniques for Effective Prediction and Analysis of Aggregates and Particles

4-5 November 2015


Aggregation not only impacts a product’s developability, but can also affect its stability, formulation, and immunogenicity. Aggregation can occur at any stage from development to manufacturing, thus the detection, characterization and monitoring of all aggregates, visible, sub-visible and submicron particles are becoming a major task in drug development. At the Protein Aggregates & Particles conference, we aim to uncover the underlying mechanism of aggregation, from which to develop tools to detect and characterize aggregates and particles, and ultimately to design novel biotherapeutics with reduced aggregation.

Preliminary Agenda


MECHANISM OF PROTEIN AGGREGATION

Chemical Kinetics and Microfluidic Sizing for the Analysis of the Aggregation of Therapeutic Proteins


Paolo Arosio, Ph.D., Marie Curie Postdoc Fellow, Department of Chemistry, University of Cambridge


MODELING AND PREDICTION OF AGGREGATION PROPENSITY

Tuning the Aggregation Propensity of Protein Structures

Salvador Ventura, Ph.D., Professor, Biochemistry and Molecular Biology, Institute of Biotechnology and Biomedicine, University of Barcelona

Rational Design of Protein Solubility

Michele Vendruscolo, Ph.D., Professor, Department of Chemistry, University of Cambridge

Determinants and Impact of Antibody Aggregation on Production and Application

Joost Schymkowitz, Ph.D., Professor, VIB Switch Lab, Department of Cellular and Molecular Medicine, KULeuven


DETECTION, IDENTIFICATION AND CHARACTERIZATION OF AGGREGATES, PARTICULATES

Nanoparticle Tracking Analysis for Studying Aggregation Profile of Particles

Antonio Ribeiro, Ph.D., Professor, Pharmaceutical Technology, University of Coimbra
Azinhaga de Santa Comba

Hydrodynamic Diameter (by DLS) and Molecular Mass Measurement (by SLS After FFF) Can Characterize Aggregation Level of a HMW Protein not Characterizable by SE-HPLC

Peter Matthiessen, Ph.D., Senior Manager, Formulation, Fill/Finish, Baxter Innovations GmbH

New, Orthogonal Methods to Detect Protein Aggregation at High and Low Concentration

Tudor Arvinte, Ph.D., Chairman & CEO, Therapeomic, Inc.

Detection and Characterization of Visible, Sub-Visible Particles and Other Aggregates: Achievements and Challenges

Anacelia Rios Quiroz, MSc, Late Stage Pharmaceutical and Process Development, Pharmaceutical Development & Supplies, PTD Biologics Europe, (PTDE-PF), F. Hoffmann-La Roche, Ltd.


ENGINEERING PROTEIN THERAPEUTICS FOR REDUCED AGGREGATION

Engineering Antibodies for Improved Developability Properties

Chris Lloyd, Ph.D., Senior Scientist, Antibody Discovery and Protein Engineering, MedImmune




For more details on the conference, please contact: 

Mimi Langley
Senior Conference Director
Cambridge Healthtech Institute
Tel: +1 816 472 0701
Email: mlangley@healthtech.com 

For partnering and sponsorship information, please contact: 

Carol Dinerstein,
Director, Business Development
Cambridge Healthtech Institute
Tel: 1 781-972-5471
Email: dinerstein@healthtech.com 

Jason Gerardi
Business Development Manager
Cambridge Healthtech Institute
Tel: 781-972-5452
Email: jgerardi@healthtech.com